Skip to main content

Yesterday, March 23, 2016, 65 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $249.20 to $12,675,000.00.

Highlighted Stocks Traded by Insiders:

Lifetime Brands (LCUT) - FREE Research Report

Shiftan Ronald, who is Vice Chairman of Board & COO at Lifetime Brands, sold 5,616 shares at $13.12 on March 23, 2016. Following this transaction, the Vice Chairman of Board & COO owned 146,022 shares meaning that the stake was reduced by 3.7% with the 5,616-share transaction.

The shares most recently traded at $12.66, down $0.46, or 3.65% since the insider transaction. Historical insider transactions for Lifetime Brands go as follows:

  • 4-Week # shares bought: 3,207
  • 4-Week # shares sold: 32,000
  • 12-Week # shares bought: 37,190
  • 12-Week # shares sold: 32,000
  • 24-Week # shares bought: 37,190
  • 24-Week # shares sold: 32,000

The average volume for Lifetime Brands has been 30,600 shares per day over the past 30 days. Lifetime Brands has a market cap of $182.3 million and is part of the consumer goods sector and consumer durables industry. Shares are down 2.41% year-to-date as of the close of trading on Wednesday.

Lifetime Brands, Inc. designs, sources, and sells branded kitchenware, tableware, and other products used in the home in the United States and internationally. The company operates through three segments: U.S. Wholesale, International, and Retail Direct. The stock currently has a dividend yield of 1.34%. The company has a P/E ratio of 14.8. Currently, there are no analysts who rate Lifetime Brands a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LCUT - FREE

TheStreet Quant Ratings

rates Lifetime Brands as a

Scroll to Continue

TheStreet Recommends

hold

. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full

Lifetime Brands Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Memorial Resource Development (MRD) - FREE Research Report

Wyszynski Joseph, who is Shareholder at Memorial Resource Development, sold 300,000 shares at $9.98 on March 23, 2016. Following this transaction, the Shareholder owned 619,929 shares meaning that the stake was reduced by 32.61% with the 300,000-share transaction.

The shares most recently traded at $9.22, down $0.76, or 8.24% since the insider transaction. Historical insider transactions for Memorial Resource Development go as follows:

  • 4-Week # shares sold: 191,403
  • 12-Week # shares sold: 191,403
  • 24-Week # shares bought: 8,127
  • 24-Week # shares sold: 191,403

The average volume for Memorial Resource Development has been 3.5 million shares per day over the past 30 days. Memorial Resource Development has a market cap of $2.1 billion and is part of the basic materials sector and energy industry. Shares are down 40.25% year-to-date as of the close of trading on Wednesday.

Memorial Resource Development Corp., an independent natural gas and oil company, engages in the acquisition, exploitation, and development of natural gas, natural gas liquids, and oil properties primarily in North Louisiana. The company has a P/E ratio of 21.5. Currently, there are 11 analysts who rate Memorial Resource Development a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MRD - FREE

TheStreet Quant Ratings

rates Memorial Resource Development as a

sell

. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, generally high debt management risk and generally disappointing historical performance in the stock itself. Get the full

Memorial Resource Development Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Illumina (ILMN) - FREE Research Report

Epstein Robert S, who is Director at Illumina, sold 300 shares at $154.25 on March 23, 2016. Following this transaction, the Director owned 6,635 shares meaning that the stake was reduced by 4.33% with the 300-share transaction.

Henry Christian O, who is EVP & Chief Commercial Officer at Illumina, sold 2,141 shares at $155.05 on March 23, 2016. Following this transaction, the EVP & Chief Commercial Officer owned 32,538 shares meaning that the stake was reduced by 6.17% with the 2,141-share transaction.

The shares most recently traded at $152.75, down $2.30, or 1.5% since the insider transaction. Historical insider transactions for Illumina go as follows:

  • 4-Week # shares sold: 24,181
  • 12-Week # shares sold: 25,289
  • 24-Week # shares sold: 27,971

The average volume for Illumina has been 1.6 million shares per day over the past 30 days. Illumina has a market cap of $23.0 billion and is part of the health care sector and drugs industry. Shares are down 20.5% year-to-date as of the close of trading on Wednesday.

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company's sequencing by synthesis technology provides researchers with various applications and the ability to sequence mammalian genomes. The company has a P/E ratio of 47.5. Currently, there are 7 analysts who rate Illumina a buy, no analysts rate it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ILMN - FREE

TheStreet Quant Ratings

rates Illumina as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Illumina Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.